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ABSTRACT 
 
 
Sepsis is the body’s response to an overwhelming infection and is a serious consequence 
of critical illness. It can cause tissue damage, organ failure, and death. Sepsis continues to have 
an unacceptably high mortality rate, due to the lack of effective treatments. Specific therapeutic 
targets for sepsis remain elusive since the complex functional changes that result in a septic state 
remain poorly understood. Macrophage Scavenger Receptor A (SRA, CD204) is a surface 
receptor that binds negatively charged, endogenous and exogenous ligands. We have discovered 
that SRA plays a significant role in the pathophysiology of sepsis. We have shown that mice 
with SRA have increased inflammation, decreased survival, and increased bacterial burden 
compared to SRA deficient mice. We have also found an increase in the expression of SRA on 
monocytes and macrophages in septic wild type mice. To determine the mechanism responsible 
for increased SRA expression in sepsis we treated a mouse macrophage cell line, (J774a.1), with 
mediators that stimulate toll like receptors (TLRs), innate immune receptors which are activated 
in sepsis. The cells were cultured with ultra pure LPS (a TLR 4 ligand), PAM3CSK4 (a TLR 2 
ligand), glucan (a Dectin-1 ligand), ultra pure LPS and PAM3CSK4, or ultra pure LPS and 
glucan for 24 hours. The cells were stained with an SRA antibody, and flow cytometry was used 
to measure the SRA expression for each treatment group. LPS treatment alone resulted in a 
significant increase in SRA expression when compared to control cells. Specifically, LPS 
increased SRA expression by 53.4% compared to media alone (p<0.05). PAM3CSK4 alone or in 
combination with LPS had no significant effect on SRA expression when compared to control 
cells. Glucan alone had no significant effect on SRA expression when compared to control cells, 
but glucan in combination with LPS did significantly increase SRA expression 47.7% (p<0.01). 
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From these data we can conclude that an increase in SRA expression on macrophages in sepsis is 
mediated by TLR4 stimulation, but not by TLR2 or Dectin-1 stimulation. 
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INTRODUCTION 
 
Sepsis syndrome and septic shock are the foremost causes of death in intensive care units 
(ICU) (1). The number of individuals that acquire sepsis continues to grow with approximately 
751,000 patients developing sepsis syndrome per year in the Unites States. The average mortality 
rate for sepsis-infected patients is 28.6% or 215,000 individuals per year (2). Sepsis is thought to 
commence following a serious injury or infection and creates an overwhelming inflammatory 
response. Sepsis may lead to or co-develop along with multiple organ dysfunction syndrome 
(MODS), systematic inflammatory response syndrome (SIRS), or acute respiratory distress 
syndrome (ARDS).  MODS occurs in approximately 30% of septic individuals (3, 4). With 
ARDS the lung is the most frequently damaged organ, but other organs like the kidneys, brain, 
and heart may also be affected (3, 4, 5). Individuals that survive sepsis are typically found to 
have diminished function mentally and physically (6). 
The underlying mechanisms that result in a septic state are complex and poorly 
understood; however, it is known that the activation of pattern recognition receptors (PRR) by 
their cognate pathogen associated molecular patterns (PAMPs) promotes an inflammatory state 
(7).  In the cases of overwhelming infection, such as sepsis, this results in an overwhelming 
stimulation of these receptors, and thus, overwhelming inflammation.  The toll like receptors 
(TLR), including TLR2 and 4 are known to play a role in the pathophysiology of sepsis, 
explaining the use of PAM3CSK4, a TLR2 ligand and gram positive microbe, and LPS, a TLR4 
ligand and gram negative microbe (8). Specifically, SRA is known to co-associate with TLR4 in 
sepsis, which is associated with the inflammatory response involving NFκB activity and cytokine 
production (9). TLR2 and Dectin-1 are expressed on neutrophils and other leukocytes. TLR2 
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stimulation has been reported to increase SRA expression in murine bone marrow. Glucan, a 
Dectin-1 ligand and fungal microbe, has also been found in sepsis (10, 11). 
Macrophage scavenger receptor class A (SRA, CD204) is a type 2 membrane receptor 
classically expressed by macrophages that binds to negatively charged endogenous (oxidized 
LDL, apoptotic cells) (8, 12) and exogenous ligands (endotoxin, glucan) (12, 13).  SRA 
regulation has been found to be up regulated by NF-κB in response to cytokines in macrophages 
and by p38 MAP kinase in response to LDL (14, 15). SRA’s role in atherosclerosis is best 
understood; however, SRA also seems to play a role in the innate immune response to infection 
(14). 
We have found that SRA plays a significant role in the morbidity and mortality of sepsis. 
Specifically, we as well as others, have discovered that wild type cecal ligation and puncture 
(CLP) induced septic mice have increased inflammation, increased bacterial burdens, and 
decreased survival, when compared to SRA knock-out mice (16, 17). Interestingly, SRA has 
been found to be protective in several other infections (18, 19). Furthermore, we have found that 
wild type mice have an increased SRA expression on spleen, bone marrow, and blood monocytes 
and macrophages. These findings denote the important role that SRA plays in the 
pathophysiology of sepsis (16). For this reason we hypothesize that mediators present in sepsis 
result in an increase in SRA expression that contributes to sepsis and septic sequelae. The goal of 
the present study is to determine a mechanism responsible for increased SRA expression on 
macrophages in sepsis.  
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 METHODS 
 
J774a.1 Cell Culture 
The murine macrophage cell line, J774a.1, was cultured in a Dulbecco’s Modification of 
Eagle’s Medium (DMEM, ATCC) with 9% newborn calf serum, 1% fetal bovine serum, and 
antibiotics at a 0.4×106/ well plating density. J774a.1 cells were cultured in 6-well plates with 
3mL DMEM and treated using PAM3CSK4 (Invivogen, 10 µg/ml), glucan (10 µg/ml), ultrapure 
LPS (upLPS, Invivogen, 100 ng/ml), a combination of PAM3CSK4 and ultrapure LPS, a 
combination of glucan and ultrapure LPS, or media alone and incubated at 37°C for 24 hours. 
 
Flow Cytometry    
The adhered cells were washed and covered with 500 µL Dulbecco’s Phosphate Buffered 
Saline (DPBS) and incubated at 37°C for 5-10 minutes. The adhered cells were then scraped into 
DPBS using pipet tips, collected, and pelleted at 2000 rpm for 5 minutes. Cells were blocked in 
PBS supplemented with 5% normal rabbit serum (NRS), 0.5% bovine serum albumin (BSA), 
0.1% sodium azide, and 5mM EDTA with anti-mouse CD16/CD32 (BD Pharmingen) before 
staining with 40 µL of mixture added to each sample. SRA was stained using rat anti-mouse 
SRA CD204 FITC (AbD Serotec, Oxford, UK) at 1:10 dilution in 10 µL stain buffer or the 
isotype control anti-body FITC rat IgG2a (BD Pharmingen) at 4:10 dilution in 10 µL stain 
buffer. BD Pharmingen suggested protocol was used in the staining process. After incubating 24 
hours at 4°C the cells were suspended with 250 µL BD Pharmingen Stain Buffer (BSA), and 
SRA mean fluorescence was measured by a FACScalibur flow cytometer and analyzed using 
CellQuest software (BD Biosciences, Mountain View, CA).  
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Data Analysis 
Each experiment was run in at least triplicate with an N = 3/ treatment group.  The SRA 
mean fluorescence was recorded for each sample.  The data are represented as mean and standard 
error of the mean for each group.  Analysis of variance (ANOVA) and Holm-Sidak method were 
used to compare the means between the groups.  P values of 0.05 or less were considered 
statistically significant. The SRA mean fluorescence results for each treatment group were then 
compiled into bar graphs. 
 
RESULTS 
 
The procedure of treating and staining the murine J774a.1 cells had three experimental 
replicates with 6 groups in each replicate and N=3 in each group. Once the SRA mean 
fluorescence for each replicate was recorded and a one-way ANOVA was run, the average of 
SRA mean fluorescence for the replicates of each treatment group were determined and bar 
graphs were created. Figure 1, displays the significant increase in SRA expression seen with the 
murine J774a.1 cells that were treated with ultra pure LPS compared to the control group. 
Specifically, murine J774a.1 cells treated with ultra pure LPS increased SRA expression by 
53.4% compared to the media alone. Figure 1 also shows that in cells treated with PAM3CSK4 
alone or PAM3CSK4 in combination with ultra pure LPS, SRA expression was not significantly 
affected by treatment.  
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Figure 1. Murine J774a.1 cells were treated with PAM3CSK4, ultra pure LPS, or a combination of both 
and incubated for 24 hours. Cells were stained for SRA and analyzed by flow cytometry for SRA mean 
fluorescence. Cells treated with ultra pure LPS alone show a significant increase in SRA expression. 
(*indicates p≤0.01) 
 
Figure 2, displays the significant increase in SRA expression seen with the murine 
J774a.1 cells that were treated with ultra pure LPS alone and in combination with glucan 
compared to the control group. Specifically, murine J774a.1 cells treated with ultra pure LPS in 
combination with glucan increased SRA expression by 47.7% compared to the media alone, 
control. Figure 2 also shows that cells treated with glucan alone were not significantly affected 
by treatment.  
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Figure 2. Murine J774a.1 cells were treated with glucan, ultra pure LPS, or a combination of both and 
incubated for 24 hours. Cells were stained for SRA and analyzed by flow cytometry for SRA mean 
fluorescence. Cells treated with LPS alone and in combination with glucan both show a significant 
increase in SRA expression. (*indicates p≤0.01) 
 
DISCUSSION 
 
This study produced a few important observations. One of the most important results 
observed was the 53.4% increase in SRA mean fluorescence when murine J774a.1 cells were 
treated with LPS, a TLR4 ligand. This suggests that TLR4 stimulation increases SRA expression 
on murine macrophages. This supports the idea that SRA plays a significant role in the morbidity 
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and mortality of sepsis via interaction or co-associating with TLR4 throughout sepsis. TLR4 is 
known to induce NFκB activity and to produce cytokines (14). Therefore, when SRA and TLR4 
co-associate, the response TLR4 has from endogenous and exogenous ligands that are released 
during sepsis is heightened, which results in greater NFκB activity and greater inflammatory 
cytokine production. This stimulation of TLR4 is likely due to specific pathogen-associated 
molecular patterns (PAMPs) released during sepsis since it is known that SRA facilitates 
bacterial uptake like LPS and LTA (20). It has also been found that SRA deficient mice have a 
greater presence of bacteria in the blood in specific infections like Listeria monocyotgenes and 
Neisseria meningitides septicemia, but in Pneumocystis carinii infection SRA deficient mice 
were more effective at removing the organism from the lungs than the wild type mice controls 
(18, 19). This observation suggests that if the interaction between SRA and TLR4 or the 
activation of TLR4 by the LPS PAMP was blocked, then lower NFκB activity and cytokine 
production would be observed, thus reducing the overall inflammatory response with sepsis.  
Another finding was that there was no significant increase in the SRA mean fluorescence 
for murine J774a.1 cells treated with PAM3CSK4, a TLR2 ligand, or glucan, a Dectin-1 ligand. 
This result indicates that TLR2 and Dectin-1 stimulation does not significantly increase SRA 
expression. However, when murine J774a.1 cells were treated with LPS and PAM3CSK4 there 
was no significant increase, suggesting that TLR2 stimulation or its activation by the 
PAM3CSK4 PAMP, prevents the increase in SRA expression seen in cells treated with LPS, 
stimulating TLR4. This may suggest a treatment strategy for sepsis, i.e. a treatment that 
stimulates TLR2 in order to prevent the significant increase in SRA expression observed in 
TLR4 stimulation alone. If this significant increase in SRA expression is prevented, then the 
overall inflammatory response to sepsis could be reduced. Further research needs to be done to 
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determine the role TLR2 stimulation plays in preventing the increase in SRA expression with 
TLR4 stimulation. In contrast, when murine J774a.1 cells were treated with glucan and LPS in 
combination, SRA was still significantly increased due to the probable interaction of TLR4 and 
SRA. Therefore, Dectin-1 stimulation in combination with TLR4 stimulation does not inhibit the 
significant increase in SRA expression found with TLR4 stimulation alone. 
To conclude, our results support the concept that TLR4 interacts with SRA to increase 
expression in the inflammatory response in sepsis. Further research is needed to determine the 
specific interaction between SRA and TLR4, to determine a mechanism to block this interaction 
or activation of TLR4 by the LPS PAMP. This blocking could result in a reduced inflammatory 
response in sepsis. Further research is also needed to determine the mechanism by which TLR2 
stimulation prevents the increase in SRA expression with TLR4 stimulation in combination. 
With further research and determination of the mechanism responsible for these results, a 
treatment for reducing the overall inflammatory response in sepsis could be developed.  
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